About this Journal Submit a Manuscript Table of Contents

Psoriasis: Updates in Immunopathogenesis and Therapies

Call for Papers

For many years, psoriasis was largely recognized as a Th1 disease and biologic agent targeting tumor-necrosis factor which has been extensively utilized to treat psoriasis and psoriatic arthritis. In the past few years, the paradigm has shifted favoring a Th17 pathway in the pathogenesis of psoriasis. Consequently, an approved biologic agent targeting IL-12 and IL-23 has demonstrated efficacy in the treatment of psoriasis and psoriatic arthritis. Currently, there are several biologic agents in development that target either IL-17 or the receptor for IL-17 in treating psoriatic disease. In addition, small molecules are being investigated for treating psoriatic disease that targets JAK kinases and phosphodiesterase 4.

We invite authors to contribute original research articles as well as review articles that discuss the immunopathogenesis of psoriasis. The inflammatory cascade of psoriasis is complex and there are many pathways that contribute to this disease. Potential topics include, but are not limited to:

  • The role of tumor necrosis factor in the pathogenesis of psoriatic disease
  • Therapies targeting tumor necrosis factor in the treatment of psoriatic disease
  • General review of Th17 cells and the cytokines they produce
  • Role of IL-23 in the pathogenesis of psoriasis
  • Therapies targeting IL-12 and IL-23 or IL-23 alone in the treatment of psoriatic disease
  • Discussion on IL-17 and its receptor and its role in psoriasis
  • New therapies that target IL-17 in the treatment of psoriasis
  • General review of the JAK kinase pathway
  • Therapies that target JAK kinase in the treatment of psoriatic disease
  • General review of phosphodiesterase 4 and cAMP
  • Therapies that target phosphodiesterase 4 in the treatment of psoriatic disease
  • A review of the different genes that are implicated in psoriasis and psoriatic arthritis

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/cdi/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/cdi/psor/ according to the following timetable:

Manuscript DueFriday, 18 April 2014
First Round of ReviewsFriday, 11 July 2014
Publication DateFriday, 5 September 2014

Lead Guest Editor

  • Paul S. Yamauchi, David Geffen School of Medicine at UCLA, Dermatology Institute & Skin Care Center, Santa Monica, CA, USA

Guest Editors

  • April Armstrong, UC Davis Health System, Department of Dermatology, Sacramento, CA, USA
  • Clive Liu, Indiana University Medical Center, Department of Dermatology, Indianapolis, IN, USA
  • Henry Wong, Ohio State University, Comprehensive Cancer Center, Columbus, OH, USA